<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Modi G</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>U.S. Department of Energy</funding><funding>NIAID NIH HHS</funding><funding>Brandeis University</funding><pagination>3062-3076</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9575405</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(11)</volume><pubmed_abstract>Many bacterial pathogens, including &lt;i>Staphylococcus aureus&lt;/i>, require inosine 5'-monophosphate dehydrogenase (IMPDH) for infection, making this enzyme a promising new target for antibiotics. Although potent selective inhibitors of bacterial IMPDHs have been reported, relatively few have displayed antibacterial activity. Here we use structure-informed design to obtain inhibitors of &lt;i>S. aureus&lt;/i> IMPDH (&lt;i>Sa&lt;/i>IMPDH) that have potent antibacterial activity (minimal inhibitory concentrations less than 2 μM) and low cytotoxicity in mammalian cells. The physicochemical properties of the most active compounds were within typical Lipinski/Veber space, suggesting that polarity is not a general requirement for achieving antibacterial activity. Five compounds failed to display activity in m</pubmed_abstract><journal>ACS infectious diseases</journal><pubmed_title>The Enzymatic Activity of Inosine 5'-Monophosphate Dehydrogenase May Not Be a Vulnerable Target for &lt;i>Staphylococcus aureus&lt;/i> Infections.</pubmed_title><pmcid>PMC9575405</pmcid><funding_grant_id>DE-AC02-06CH11357</funding_grant_id><funding_grant_id>1R21AI138048</funding_grant_id><funding_grant_id>Sprout Award</funding_grant_id><funding_grant_id>R21 AI138048</funding_grant_id><funding_grant_id>HHSN272201700060C</funding_grant_id><funding_grant_id>R01 AI125362</funding_grant_id><funding_grant_id>R01AI125362</funding_grant_id><pubmed_authors>Hedstrom L</pubmed_authors><pubmed_authors>Joachimiak A</pubmed_authors><pubmed_authors>Rothstein DM</pubmed_authors><pubmed_authors>Cullinane RT</pubmed_authors><pubmed_authors>Zhang M</pubmed_authors><pubmed_authors>Lawson AP</pubmed_authors><pubmed_authors>Cuny GD</pubmed_authors><pubmed_authors>Marqus GM</pubmed_authors><pubmed_authors>Manna AC</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Kuzmic P</pubmed_authors><pubmed_authors>Kim Y</pubmed_authors><pubmed_authors>Snider BB</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Cheung A</pubmed_authors><pubmed_authors>Vippila MR</pubmed_authors><pubmed_authors>Chacko S</pubmed_authors><pubmed_authors>Maltseva N</pubmed_authors><pubmed_authors>Kotler JLM</pubmed_authors><pubmed_authors>Modi G</pubmed_authors><pubmed_authors>Gollapalli DR</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Enzymatic Activity of Inosine 5'-Monophosphate Dehydrogenase May Not Be a Vulnerable Target for &lt;i>Staphylococcus aureus&lt;/i> Infections.</name><description>Many bacterial pathogens, including &lt;i>Staphylococcus aureus&lt;/i>, require inosine 5'-monophosphate dehydrogenase (IMPDH) for infection, making this enzyme a promising new target for antibiotics. Although potent selective inhibitors of bacterial IMPDHs have been reported, relatively few have displayed antibacterial activity. Here we use structure-informed design to obtain inhibitors of &lt;i>S. aureus&lt;/i> IMPDH (&lt;i>Sa&lt;/i>IMPDH) that have potent antibacterial activity (minimal inhibitory concentrations less than 2 μM) and low cytotoxicity in mammalian cells. The physicochemical properties of the most active compounds were within typical Lipinski/Veber space, suggesting that polarity is not a general requirement for achieving antibacterial activity. Five compounds failed to display activity in m</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2026-05-27T19:09:13.265Z</modification><creation>2025-02-19T03:22:53.024Z</creation></dates><accession>S-EPMC9575405</accession><cross_references><pubmed>34590817</pubmed><doi>10.1021/acsinfecdis.1c00342</doi></cross_references></HashMap>